Catalysts / CCCC
Upcoming FDA decisions and readouts we track for C4 Therapeutics, each with the filing that announced it.
FreeBioList tracks 4 upcoming catalysts for C4 Therapeutics (CCCC, listed on Nasdaq). They cover 3 programmes: Cemsidomide (Multiple myeloma — biomarker data at IMS Annual Meeting), Cemsidomide + elranatamab (Multiple myeloma — dose escalation progress; Multiple myeloma) and Cemsidomide + dexamethasone (Relapsed/refractory multiple myeloma).
First on the list: the Phase 1 readout for Cemsidomide (Multiple myeloma — biomarker data at IMS Annual Meeting), guided by the company to Sep 2026. The furthest-out event tracked is H2 2027. By stage, the upcoming rows are 1 Phase 1 readout, 2 Phase 1B readouts and 1 Phase 2 readout.
All 4 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| C4 Therapeutics CCCC · Nasdaq | Cemsidomide | Multiple myeloma — biomarker data at IMS Annual Meeting | Sep 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| C4 Therapeutics CCCC · Nasdaq | Cemsidomide + elranatamab | Multiple myeloma — dose escalation progress | H2 2026 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| C4 Therapeutics CCCC · Nasdaq | Cemsidomide + elranatamab | Multiple myeloma | Mid 2027 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| C4 Therapeutics CCCC · Nasdaq | Cemsidomide + dexamethasone | Relapsed/refractory multiple myeloma | H2 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList